Premium
Anticonvulsant activity of melatonin against seizures induced by quinolinate, kainate, glutamate, NMDA, and pentylenetetrazole in mice
Author(s) -
Lapin Lzyaslav P.,
Mirzaev Said M.,
Ryzov Ivan V.,
Oxenkrug Gregory F.
Publication year - 1998
Publication title -
journal of pineal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 131
eISSN - 1600-079X
pISSN - 0742-3098
DOI - 10.1111/j.1600-079x.1998.tb00535.x
Subject(s) - quinolinate , quinolinic acid , melatonin , convulsant , kainate receptor , pharmacology , kainic acid , chemistry , anticonvulsant , glutamate receptor , kynurenic acid , endocrinology , medicine , biology , epilepsy , biochemistry , ampa receptor , receptor , tryptophan , neuroscience , amino acid
Melatonin was tested in an ongoing attempt to find the endogenous antagonists of quinolinic acid, an endogenous convulsant. Among a great number of metabolites that have been tried before, only a few were found (cerulein and quinaldic acid in mice and kynurenic acid in rats). In SHR (bred from Swiss) male mice, intracerebroventricular (i.c.v.) pretreatment with melatonin (1.25–10.0 μg) attenuated (in the descending order of potency) the convulsant effect of i.c.v. administered kainate, quinolinate, glutamate, N‐methyl‐D‐aspartate, and pentylenetetrazole. Melatonin was ineffective against i.p. administered pentylenetetrazole. Systemically (intraperitoneal, i.p.) administered melatonin (12.5–100.0 mg/kg) attenuated the convulsant effect of quinolinate, while the action of other convulsants used remained unaltered. It is suggested that melatonin could be tried against grand ma1 seizures in epileptic patients.